NCT07617597 Deuruxolitinib Phosphate Alopecia Areata Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07617597—Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata (THRIVE-AAJP)—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why NCT07617597 is a hot trial to watch
Alopecia Areata is no longer one homogeneous development market. The most consequential programs increasingly compete through a specific mechanism, biomarker, treatment line, delivery strategy or endpoint architecture. NCT07617597 is notable because it tests Deuruxolitinib Phosphate in a Phase 3 design with Percentage of subjects achieving an absolute SALT score of 20 or less as a primary decision variable. The wider PatSnap topic query returned 189 trial records and 134 result records, so differentiation depends on evidence quality rather than activity alone.
PatSnap Clinical Trials MCP makes the protocol fields machine-readable, while the companion asset and organization servers add mechanism and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07617597 |
| Official title | Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata (THRIVE-AAJP) |
| Phase / status | Phase 3 / Recruiting |
| Intervention | Deuruxolitinib Phosphate |
| Sponsor | Sun Pharma Japan Ltd. |
| Geography | Japan |
| Enrollment | 78 |
| Primary endpoint | Percentage of subjects achieving an absolute SALT score of 20 or less |
| Endpoint time frame | Week 24 |
| Primary completion | 2028-02-01 |
| Study completion | 2028-09-01 |
Design and endpoint interpretation
The design should be read as an evidence architecture, not just a phase label. The primary endpoint—Percentage of subjects achieving an absolute SALT score of 20 or less—determines what uncertainty this study can resolve. The reported time frame is Week 24. Enrollment of 78 participants and geography in Japan shape statistical precision, operational risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.
Benchmark readouts in the same clinical field
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial (Phase 3): SALT20(24-week) = 38.3 % ; SALT20(24-week) = 33.0 % ; SALT20(24-week) = 0.8 % .
- The real-world impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM (Not Applicable): EB/EL ClinROs(MID change(12-month)) = 6.0 Pts .
- Early improvement in scalp hair regrowth with deuruxolitinib in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials (Phase 3): SALT10(W12) = 10.6 % ; SALT10(W12) = 4.6 % ; -.
These result records are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, line of therapy, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.
Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: Deuruxolitinib Phosphate (Approved; JAK1 x JAK2).
Company & Deal Intelligence context: Sun Pharma Japan Ltd. — https://jp.sunpharma.com.
The sponsor profile matters because a trial's strategic value depends on more than scientific rationale. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes that connect biological activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: randomized data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world care settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety monitoring or durability.
What to monitor next
Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.
Bottom line
NCT07617597 is a focused lens on Alopecia Areata development. Its value will be determined by whether Deuruxolitinib Phosphate can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from topic-level benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
